The dihydroorotate dehydrogenase inhibitor leflunomide triggers transcriptional up‐regulation of the mitochondrial fusion factors MFN1 and MFN2 (Miret‐Casals et al, 2018) and has been tested in murine obesity models. The gene discussed is MFN2; the disease is Obesity.